Clinical Trial Update: The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis [Phase 4]

View source ↗

Summary

Phase 4 trial investigating F-18 Florbetapir for early detection of Cardiac Amyloidosis; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Amyloidosis

Drugs mentioned

• F-18 Florbetapir (florbetapir)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Cardiac Amyloidosis | Phase 4 | Status: TERMINATED | Results posted: 2021-07-27